Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 533-533 ◽  
Author(s):  
A. Brufsky ◽  
W. G. Harker ◽  
J. T. Beck ◽  
R. Carroll ◽  
E. Tan-Chiu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Cancer Treatment ◽  
Postmenopausal Women ◽  
Early Breast Cancer

The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial

Oncology ◽  
2011 ◽  
Vol 81 (5-6) ◽  
pp. 298-305 ◽  
Author(s):  
Tamar Safra ◽  
Rinat Bernstein-Molho ◽  
Julia Greenberg ◽  
Sharon Pelles-Avraham ◽  
Irina Stephansky ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Protective Effect ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Randomized Phase Ii

The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: 36-month follow-up.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e11111-e11111 ◽  
Author(s):  
J. Greenberg ◽  
S. M. Stemmer ◽  
R. Bernstein-Molho ◽  
S. Pelles-Avraham ◽  
I. Stephansky ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Protective Effect ◽  
Postmenopausal Women ◽  
Early Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document